These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 20506310)

  • 21. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
    Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
    J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
    Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
    Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
    Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
    Söderlin MK; Petersson IF; Geborek P
    Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study.
    Heinonen AV; Aaltonen KJ; Joensuu JT; Lähteenmäki JP; Pertovaara MI; Romu MK; Hirvonen HE; Similä AK; Blom ML; Nordström DC
    J Rheumatol; 2015 Dec; 42(12):2339-46. PubMed ID: 26472421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
    Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.
    Chen JS; Makovey J; Lassere M; Buchbinder R; March LM
    Arthritis Care Res (Hoboken); 2014 Mar; 66(3):464-72. PubMed ID: 24022870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Symmons DP; Watson KD; Silman AJ;
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
    Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
    Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis.
    da Silva BS; Bonfá E; de Moraes JC; Saad CG; Ribeiro AC; Gonçalves CR; de Carvalho JF
    Biologicals; 2010 Sep; 38(5):567-9. PubMed ID: 20638299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.
    Kristensen LE; Englund M; Neovius M; Askling J; Jacobsson LT; Petersson IF
    Ann Rheum Dis; 2013 Oct; 72(10):1675-9. PubMed ID: 23148309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
    Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
    Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months.
    Mathieu S; Pereira B; Couderc M; Rabois E; Dubost JJ; Soubrier M
    Rheumatology (Oxford); 2013 Jan; 52(1):204-9. PubMed ID: 23065359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
    Conti F; Ceccarelli F; Marocchi E; Magrini L; Spinelli FR; Spadaro A; Scrivo R; Valesini G
    Ann Rheum Dis; 2007 Oct; 66(10):1393-7. PubMed ID: 17613555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS; Nordvåg BY; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.
    Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Rødevand E; Koldingsnes W; Kaufmann C; Kvien TK
    Ann Rheum Dis; 2011 Jan; 70(1):157-63. PubMed ID: 21062852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.